1. Medtech Insight
  2. >>Policy & Regulation

Senate Boost To US FDA Device Spending Falls Short of House's Bid

 
• By Sue Darcey

The Senate would provide US FDA’s device program with a slight 2.2% boost in 2019 spending, to $299.99m, under numbers approved by the Senate Appropriations Committee May 24. But device activities ultimately could see a lot more next fiscal year, as the House is seeking $368.24m.

Capitol House

The US Senate wants to give FDA’s device programs $299.99m in congressional budget authority to spend in FY 2019. The amount would include $6m for medtech manufacturing, and a portion of a proposed $70m in 21st Century Cures funding to be divided among three FDA centers.

That is far less generous than the $368.24m the US House wants to provide in 2019. (Also see "House Panel Approves Boosts For FDA Digital Health Plan, Quality Medtech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.